Shanghai Henlius Biotech, Inc. (2696.HK) e Organon (NYSE: OGN) anunciaram hoje que a Agência Europeia de Medicamentos (EMA) validou o pedido de autorização de comercialização (MAA ...
International growth was particularly strong in the LAMERA region, with tender expansions and robust performance in Brazil ..
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN ... primarily driven by the timing of tenders in Brazil for Ontruzant® (trastuzumab-dttb) and Brenzys™ (etanercept) as well as a 16% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback